AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

14,318.00p
   
  • Change Today:
    256.00p
  • 52 Week High: 15,316.00
  • 52 Week Low: 10,120.00
  • Currency: UK Pounds
  • Shares Issued: 1,551.01m
  • Volume: 3,706,707
  • Market Cap: £222,074m
  • RiskGrade: 123
  • Beta: 0.00

Latest ShareCast News

Astrazeneca secures US approval for Truqap combo in PTEN‑deficient prostate cancer

By Iain Gilbert

Date: Monday 15 Jun 2026

(Sharecast News) - Drugmaker Astrazeneca said on Monday that its cancer drug Truqap, used with abiraterone and prednisone, has been approved in the US as the first targeted treatment for a form of advanced prostate cancer driven by a fault in the PTEN gene.

AstraZeneca ShareCast News

Astrazeneca's Imfinzi receives green light from ... 29-May-2026 ShareCast
US FDA pushes back decision on Astrazeneca's cam... 27-May-2026 ShareCast
Astrazeneca's Camizestrant cleared in the EU, En... 26-May-2026 ShareCast
Citi sees buying opportunity at AstraZeneca afte... 18-May-2026 ShareCast
AstraZeneca secures US approval for two drugs 18-May-2026 ShareCast

AstraZeneca Regulatory News

Truqap approved in US for prostate cancer 15-Jun-2026 07:00 RNS
Admission of Further Securities to Trading 01-Jun-2026 15:05 RNS
Total Voting Rights 01-Jun-2026 15:00 RNS
Imfinzi approved in US for early bladder cancer 29-May-2026 07:00 RNS
US FDA decision date on camizestrant extended 27-May-2026 07:00 RNS

AstraZeneca Newspaper Links

Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent
MARKET REPORT: Ariad on the up amid growing spec... 04-Dec-2014 Daily Mail
Some reasons why Pfizer won’t bid for AstraZenec... 19-Nov-2014 Guardian
Pfizer unlikely to try AstraZeneca takeover agai... 07-Nov-2014 Guardian

AstraZeneca Tips & Analysis

Questor :AstraZeneca 29-Apr-2014 Telegraph
Questor : AstraZeneca 24-Jan-2014 Telegraph
Questor:AstraZeneca 22-Dec-2011 Telegraph
Investment Column:AstraZeneca 28-Oct-2011 The Independent
Investment Column: AstraZeneca 23-Jun-2011 The Independent

AstraZeneca News Wires

MedImmune Announces Zook as President 13-Nov-2008 PR Newswire
Survey Shows Lung Cancer Patients Blamed for The... 12-Nov-2008 PR Newswire
CRESTOR Demonstrates Dramatic CV Risk Reduction ... 09-Nov-2008 PR Newswire

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 14,318.00p
Change Today 256.00p
% Change 1.82 %
52 Week High 15,316.00
52 Week Low 10,120.00
Volume 3,706,707
Shares Issued 1,551.01m
Market Cap £222,074m
Beta 0.00
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average
90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average
Price Trend
9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average
45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average
Income
68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average
Sector averageSector averageSector averageSector averageSector average
Growth
87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 13
Neutral 3
Sell 0
Strong Sell 1
Total 27
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 19-Feb-26 07-Aug-25
Paid 23-Mar-26 08-Sep-25
Amount 217.00¢ 103.00¢

Trades for 26-Jun-2026

Time Volume / Share Price
16:35 81,762 @ 14,318.00p
15:59 383,609 @ 14,038.00p
15:59 383,609 @ 14,038.00p
17:12 370,974 @ 14,038.00p
16:51 128 @ 14,318.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page